A meta-analysis [9] found that CKD patients including predialysis and dialysis with erythropoiesis-stimulating agents (ESAs) targeting the higher Hb do not lower mortality and may increase cardiovascular risk. The gene discussed is GSTM1; the disease is chronic kidney disease.